Dr. Robert Hariri, Founder and CEO of Celularity sits down with his fellow Director Dr. Andrew Pecora to speak with Max Gomez at the Fifth International Vatican Conference to discuss “Immunotherapy”

Dr. “Bob” Hariri is world-renown for his paradigm shifting research, development, manufacturing, and logistical breakthroughs in stem cell therapy research. Famously, Bob Hariri discovered the “stem-cell factory” qualities inherent in every full-term healthy pregnancy... the human placenta. An estimated 140+ million placentas are discarded as medical bio hazardous waste after the natural course of delivering a newborn, empowering Dr. Hariri’s team to up-cycle this abundant natural resource into allogeneic, off the shelf, cellular therapies.

An absolute must view conversation takes you to the seem of the curtain, as you are given a rare peek into the future of combatting degenerative diseases.

Within our lifetimes, we can expect to witness curative measures against the likes of cancer, infectious disease, and even many of the degenerative diseases before considered “off-limits” to efficacious treatments. Celularity may one day become synonymous with the concept of improved human longevity and health.

More about the individuals in the video:


Dr. Robert Hariri: Dr. Bob Hariri is an accomplished surgeon, biomedical scientist, and serial entrepreneur in two technology sectors, biomedicine and aerospace. He is the chairman, founder, and chief executive officer of Celularity, Inc., one of the world's leading human cellular therapeutics companies. Dr. Hariri was the founder and CEO of Anthrogenesis Corporation, and after its acquisition by Celgene Corporation, served as CEO of Celgene Cellular Therapeutics. Dr. Hariri also co-founded the genomic-based health intelligence company, Human Longevity, Inc.

Dr. Hariri pioneered the use of stem cells to treat a range of life-threatening human diseases and continues today to make transformative contributions in the fields of immuno-oncology and cell therapeutics along with tissue engineering and functional regeneration. He is widely acknowledged for his discovery of pluripotent stem cells derived from the human placenta, and as a member of the team that discovered the physiological activities of tumor necrosis factor (TNF). He holds over 150 issued and pending patents for discoveries including placenta-derived stem cells, which Nature recognized as one of the ten most important patent estates in the field. He has authored over 150 published chapters, articles, and abstracts.

Dr. Hariri twice received the Thomas Alva Edison Award for technological innovation, in 2007 and 2011, and is a recipient of the Children’s Brain Tumor Foundation’s Fred J. Epstein Lifetime Achievement Award. Over the years, he has received numerous honors for his many contributions to the fields of biomedicine and aviation.

Dr. Hariri is an adjunct associate professor of pathology at the Icahn School of Medicine at Mount Sinai. He is a former member of the board of visitors of the Columbia University School of Engineering and Applied Sciences and the Science & Technology Council of the College of Physicians and Surgeons. He is a member of the X PRIZE Foundation scientific advisory board for the Archon X PRIZE for Genomics. Dr. Hariri is a trustee and vice-chair of the Liberty Science Center. In 2010 he was appointed a Commissioner of Cancer Research by New Jersey Governor Chris Christie.

Dr. Hariri completed his undergraduate training at Columbia University School of Engineering and Applied Sciences and Columbia College. He received his M.D. and Ph.D. degrees from Cornell University, where he was the recipient of both the Julian R. Rachele Award and the Doctoral Dissertation Award. He completed his surgical training at The New York Hospital-Cornell Medical Center.

Dr. Andrew Pecora:

A nationally recognized expert in care transformation, Andrew L. Pecora, M.D., FACP, CPE, is at the forefront of the health-systems improvement movement. As chief executive officer of Outcomes Matter Innovations (OMI), he is a national advocate for making medical practices more efficient and profitable and, at the same time, improving patient care. Dr. Pecora, one of Modern Healthcare’s 2019 “50 Most Influential Clinical Executives,” is dedicated to pairing practices with artificial intelligence (AI) and health technologies to increase efficiencies, reduce costs and enable physicians to better do what they do best – heal patients.

Dr. Pecora came to OMI from Hackensack Meridian Health, where he was president, Physician Enterprise Division and chief innovation officer. A certified hematologist and oncologist – and one of the world’s leading experts in blood and marrow stem cell transplantation, cellular medicine and immunology research. While at Hackensack Meridian Health, he created and expanded the John Theurer Cancer Center, named one of the United States’ top 50 cancer centers.

свернуть